Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 14/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29990658 | 1.00 | GPR119 (0.53) | GPR119MAPTALDH1A1LMNACNR1 | |
| SCHEMBL25221736 | 0.88 | GPR119 (0.53) | GPR119MAPTALDH1A1LMNACNR1 | |
| SCHEMBL20294520 | 0.87 | GPR119 (0.56) | GPR119MAPTALDH1A1LMNACNR1 | |
| SCHEMBL594965 | 0.87 | MAPT (0.56) | GPR119MAPTALDH1A1LMNAMEN1 | |
| SCHEMBL30150192 | 0.87 | MAPT (0.56) | GPR119MAPTALDH1A1LMNAMEN1 | |
| SCHEMBL29132186 | 0.86 | GPR119 (0.48) | GPR119MAPTALDH1A1LMNACNR1 | |
| SCHEMBL24671756 | 0.84 | GPR119 (0.74) | GPR119CNR1 | |
| SCHEMBL29990508 | 0.84 | GPR119 (0.74) | GPR119CNR1 | |
| SCHEMBL25204395 | 0.84 | MAPT (0.56) | GPR119MAPTALDH1A1LMNACNR1 | |
| SCHEMBL25207960 | 0.84 | GPR119 (0.50) | GPR119MAPTALDH1A1LMNACNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279202-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| CN-117916231-A | Compounds for inhibiting or degrading target proteins, compositions comprising the same, methods of making and methods of using the same | 纽力克斯治疗公司 | 2024-04-19 | — | — | CN | disclosed |
| EP-4334302-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | Nurix Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| CN-117693502-A | Compounds for inhibiting or degrading ITK, compositions comprising the same, methods of making the same, and methods of using the same | 纽力克斯治疗公司 | 2024-03-12 | — | — | CN | disclosed |
| US-20230158151-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230158151-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230158151-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| WO-2022235715-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279202-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | ITK, NFATC1, TNIK | GPR119 3873/4885MAPT 3417/4885ALDH1A1 2433/4885 |
| US-20230158151-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | MDM2, XIAP, ADRM1 | GPR119 4016/4885MAPT 505/4885ALDH1A1 3345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.